Prevalence and incidence of symmetrical symptomatic peripheral neuropathy in patients with multidrug - resistant TB

Simple item page
dc.contributor.authorConradie, F
dc.contributor.authorMabiletsa, T
dc.contributor.authorSefoka, M
dc.contributor.authoret al
dc.date.accessioned2015-06-04T11:24:11Z
dc.date.available2015-06-04T11:24:11Z
dc.date.issued2014-01
dc.departmentFamily Medicine
dc.descriptionKMen_ZA
dc.description.abstractBackground: Symptomatic symmetrical peripheral neuropathy (SSPN) is common in patients with HIV infection. It is also a common adverse event associated with both tuberculosis (TB) treatment and antiretroviral therapy (ART), particularly stavudine. While tenofovir is the one of recommended first-line nucleotide reverse transcriptase inhibitors (NRTIs), there is a risk of nephrotoxicity when using tenofovir together with the aminoglycosides needed to treat multidrug-resistant (MDR) TB. Thus, stavudine is often chosen as a treatment option for the HIV-infected MDR TB patient. Objective: To assess whether use of stavudine both before and during treatment for MDR TB increased the prevalence and incidence of SSPN. Method: MDR TB patients at Sizwe Tropical Disease Hospital were examined for signs of prevalent SSPN. Age, gender, HIV status, alcohol use, TB and HIV treatment regimens both prior to admission and current, and concomitant medications were recorded. Results: In this cohort of 246 patients, we found that 24.4% of patients with MDR TB had SSPN at time of admission for treatment of MDR TB. They were more likely to be HIV-infected (odds ratio (OR) 3.21; 95% CI 1.25 - 8.21) and tended to have longer (>7 months) exposure to stavudine (OR 1.81; 95% CI 0.90 - 3.63). Incident SSPN occurred in 17% of patients and was associated with older age (hazard ratio (HR) 3.00; 95% CI 1.30 - 6.89) and exposure to terizidone (HR 2.98; 95% CI 0.94 to 4.61) or, to a lesser extent, with stavudine (crude HR 1.62; 95% CI 0.65 - 4.01) in the first 6 months of MDR TB treatment. This common adverse event emphasises the need for the development of less toxic drugs for the treatment of MDR TB.en_ZA
dc.identifier.citationConradie ,F., Mabiletsa ,T., Sefoka ,M., et al. 2014. Prevalence and incidence of symmetrical symptomatic peripheral neuropathy in patients with multidrug - resistant TB. SAMJ;104(1):24-26en_ZA
dc.identifier.urihttp://hdl.handle.net/10539/17946
dc.language.isoenen_ZA
dc.subjectTuberculosis, Multidrug-Resistanten_ZA
dc.subjectPeripheral Nervous System Diseasesen_ZA
dc.subjectPrevalenceen_ZA
dc.subjectAdverse effectsen_ZA
dc.titlePrevalence and incidence of symmetrical symptomatic peripheral neuropathy in patients with multidrug - resistant TBen_ZA
dc.typeArticleen_ZA
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Prevalence and incidence of symmetrical symptomatic peripheral neuropathy in patients with multidrug-resistant TB.pdf
Size:
91.24 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Research Outputs (Clinical Medicine)
Academic Wits Research Outputs (All submissions)